Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

BACKGROUND: Tamoxifen, the most frequently used drug for treating estrogen receptor-positive breast cancer, must be converted into active metabolites to exert its therapeutic efficacy, mainly through CYP2D6 enzymes. The objective of this study was to investigate the impact of CYP2D6 polymorphisms on...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Hennig, Ewa E., Piatkowska, Magdalena, Karczmarski, Jakub, Goryca, Krzysztof, Brewczynska, Elzbieta, Jazwiec, Radoslaw, Kluska, Anna, Omiotek, Robert, Paziewska, Agnieszka, Dadlez, Michal, Ostrowski, Jerzy
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2015
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4522133/
https://ncbi.nlm.nih.gov/pubmed/26232141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1575-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi